EUVIMEDEUVIMED entdecken
Leitlinie

Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer

Samuel Keltner, Hope Esslinger, Xiaoyong Wu, Shesh Rai, Vinita Takiar

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.06.008 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Samuel Keltner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati OH. Hauptthemen laut MEDLINE: Lung Neoplasms, Radiosurgery, Carcinoma, Non-Small-Cell Lung, Neoplasm Staging. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Biomedical Laboratory Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Stereotactic body radiation therapy (SBRT) is a treatment for patients with early-stage non-small cell lung cancer (ES-NSCLC). Surveillance guidelines vary after treatment. While patients are more likely to locally recur within 2 years of treatment, there remains a paucity of data on the benefit of frequent and long-term surveillance. We evaluated a cohort of NSCLC patients to evaluate surveillance patterns and outcomes. MATERIALS AND METHODS: Patients with ES-NSCLC treated with SBRT were retrospectively evaluated. Imaging was reviewed after SBRT for evidence of recurrence or new malignancy. The median scan interval (MSI) was calculated as the median number of months between surveillance scans. The MSI between patients with or without new disease was compared by t-test. New disease development and survival between patients with =T2 disease and with or without prior malignancy was compared using χ², Kaplan-Meier analysis, and Gray's test. RESULTS: A cohort of 168 patients with median follow up of 23.4 months met criteria for review with 50% developing new disease. MSI did not differ between patients with or without new disease. Patients with >=cT2 tumors had worse overall survival and trended towards higher incidence of new disease. New disease continued to occur, even 5 years after treatment. CONCLUSION: Increased scan frequency did not increase detection of new disease. Patients continued to fail 5 years after treatment. Larger tumors trended toward more frequent failures and those patients experienced worse OS. Surveillance guidelines should be optimized to prevent over surveillance after treatment and to continue long-term surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsRadiosurgeryCarcinoma, Non-Small-Cell LungNeoplasm StagingNeoplasm Recurrence, LocalHumansMaleFemaleAgedRetrospective StudiesMiddle AgedFollow-Up StudiesAged, 80 and overPractice Guidelines as TopicSurvival RateAdult

Stichwörter der Autor:innen

DefinitiveMalignancyRecurrenceScreeningStage

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati OH.
  • Cancer Data Science Center, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH; Biostatistics and Bioinformatics Shared Resources, University of Cincinna…
  • Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati OH. Electronic address: takiarva@ucmail.uc.edu.

Förderung

  • Biomedical Laboratory Research and Development

Zitieren

APA

Keltner, S., Esslinger, H., Wu, X., Rai, S., & Takiar, V. (2024). Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.06.008

Vancouver

Keltner S, Esslinger H, Wu X, Rai S, Takiar V. Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.06.008

BibTeX
@article{Keltner2024,
  author = {Keltner, Samuel and Esslinger, Hope and Wu, Xiaoyong and Rai, Shesh and Takiar, Vinita},
  title = {Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.06.008}
}
Kostenlos starten →